Skip to main content

Advertisement

Table 7 Change from baseline to day 180 in serum and synovial fluid biomarkers

From: Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study

Matrix Parameter reduction Day Placebo (n) GC (n) UC-II (n)
Serum COMP (ng/mL) 180 −51.2 ± 31.3 (53) −56.5 ± 36.0 (56) −69.6 ± 40.8 (53)
CRP (mg/L) 180 15.1 ± 6.33 (26) 9.09 ± 5.36 (28) 13.0 ± 4.64 (28)
Synovial IL-6 (ng/mL) 180 −9.54 ± 4.83 (23) −9.72 ± 5.28 (24) −11.8 ± 5.37 (21)
MMP-3 (μg/mL) 180 −2.24 ± 1.26 (25) −0.93 ± 0.79 (27) −2.67 ± 1.85 (23)
  1. Values presented as Mean ± SE. Statistical analysis was performed on log transformed and baseline adjusted values. No significant differences were observed between the study groups (p > 0.05)